NCT07747090 — "A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH." trial site landscape

Public-registry site landscape for NCT07747090, “A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.”, a Paroxysmal Nocturnal Hemoglobinuria study sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07747090 (registry record)
Study title	A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
Official title	A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of FXS6837 Versus Eculizumab in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sponsor	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Condition(s)	Paroxysmal Nocturnal Hemoglobinuria
Phase	PHASE3
Listed sites	1
Site countries	China

Recruiting-density context

At TianJin Medical University General Hospital — one of the facilities listed on this trial — 1 other study is actively recruiting Paroxysmal Nocturnal Hemoglobinuria patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.

Patient-friendly overview of this study: eichor.com/study/NCT07747090.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07747090 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →